Form 4: Quest Diagnostics SVP Acquires Restricted Stock Units and Options

Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics, reports acquisition of restricted stock units and stock options, along with adjustments to existing holdings.

Summary

• Michael E. Prevoznik, a Senior Vice President and General Counsel at Quest Diagnostics, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• On February 12, 2025, Prevoznik acquired 2,345 shares of common stock through a restricted stock unit award.
• He also acquired 8,991 non-qualified stock options with an exercise price of $165.30, vesting in three equal annual installments starting February 12, 2026, and expiring on February 12, 2035.
• Additionally, 5,644 shares were disposed of from his 401(k)/SDCP.
• Following these transactions, Prevoznik directly owns 40,823 shares of common stock and indirectly owns 5,644 shares through the 401(k)/SDCP.
• He also holds 8,991 non-qualified stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating standard executive compensation practices. The acquisition of stock options and restricted stock units can be seen as a positive sign, but it's not necessarily indicative of a major shift in the company's outlook.

Positives

• The acquisition of restricted stock units and stock options suggests confidence in the company's future performance from a high-ranking executive.

Future Outlook

The vesting schedule of the stock options (three equal annual installments beginning on February 12, 2026) suggests a long-term commitment from the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in publicly traded companies, including competitors of Quest Diagnostics such as Laboratory Corporation of America (LH) and Bio-Reference Laboratories.
• The vesting schedules and exercise prices are typically structured to align executive incentives with long-term shareholder value creation, similar to practices observed at companies like Danaher Corporation (DHR) and Abbott Laboratories (ABT).

Stakeholder Impact

• The transactions reported in the Form 4 filing may have a minor impact on shareholders, as they provide insight into the executive's holdings and incentives.
• Employees may view the stock option grants as a positive sign of the company's commitment to its leadership.

Key Dates